Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 22, 2017 | June 08, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date May 22, 2017 · Filed June 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.64 · Expires 2027-05-22 | Direct | 15,000 |
Reported balance
After 2017-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-22 · Grant · Acquired 15,000 · Balance 15,000 F1: Option vests in 12 equal monthly installments beginning June 22, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 12 equal monthly installments beginning June 22, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2017 Filed Jun 8, 2017 22:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $53.64 | $0.00 |
DisclosureSEC source: 0001209191-17-038629 · doc4.xml · derivative · entry 1 MOLLICA JOSEPH A · CIK 0001126489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-17-026899 · doc4.xml · derivative · entry 3 MOLLICA JOSEPH A · CIK 0001126489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,312 | $51.80 | $67,961.60 |
DisclosureSEC source: 0001209191-17-026899 · doc4.xml · nonDerivative · entry 2 MOLLICA JOSEPH A · CIK 0001126489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,042 F1 · balance_after: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the April 12, 2017 market close price ($51.80), and this net amount ($48.40) was then multiplied by the number of options (20,000), with the resulting amount then divided by the market close price to result in a net issuance of 18,688 shares to the optionee. The 1,312 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 20,000 | $3.40 | $68,000.00 |
DisclosureSEC source: 0001209191-17-026899 · doc4.xml · nonDerivative · entry 1 MOLLICA JOSEPH A · CIK 0001126489 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the April 12, 2017 market close price ($51.80), and this net amount ($48.40) was then multiplied by the number of options (20,000), with the resulting amount then divided by the market close price to result in a net issuance of 18,688 shares to the optionee. The 1,312 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.